Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Manufacturing efficiencies supported a higher gross margin, while the first multiple sclerosis data presentation moves to October 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) reported third-quarter 2026 AUCATZYL net product revenue of $41.2 million, up 95% year over year. Gross margin reached 57%, versus 55% in the second quarter and a negative margin a year earlier. Net loss narrowed to $55.1 million, or $0.21 per ordinary share, from $79.1 million, or $0.30.
The company now expects full-year 2026 AUCATZYL revenue at or above the prior guidance’s $150 million upper end. Cash, cash equivalents and marketable securities totaled $248.4 million at September 30. Autolus expects funding into Q2 2028, including anticipated product revenue and $100 million from two Perceptive credit-facility tranches. Obe-cel received FDA regenerative medicine advanced therapy designation for lupus and lupus nephritis. Pediatric leukemia data remain expected by year-end 2027 and lupus nephritis data in 2028; the first progressive multiple sclerosis data presentation moves to October 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.2026 AUCATZYL revenue is now expected at or above the prior guidance’s $150 million upper end.
- Moderate pointAUCATZYL Q3 net product revenue rose 95% year over year to $41.2 million.
- Moderate pointQ3 gross margin reached 57%, versus 55% in Q2 2026 and a negative margin in Q3 2025.
- Moderate pointQ3 net loss narrowed to $55.091 million from $79.118 million; per-share loss improved to $0.21 from $0.30.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Funding runway into Q2 2028 is expected, including anticipated AUCATZYL revenue and $100 million from two Perceptive tranches. 28% of market cap
14 minor points
- Minor pointQ3 cost of sales fell to $17.927 million from $28.643 million a year earlier.
- Minor pointQ3 operating loss narrowed to $43.535 million from $71.621 million a year earlier.
- Minor pointQ3 selling, general and administrative expenses fell to $35.946 million from $36.280 million a year earlier.
- Minor pointCash, cash equivalents and marketable securities increased to $248.4 million from $201.6 million at June 30, 2026.
- Minor pointNine-month product revenue increased to $113.128 million from $51.049 million in the comparable 2025 period.
- Minor pointNine-month cost of sales fell to $62.963 million from $71.039 million in the comparable 2025 period.
- Minor pointNine-month research and development expenses fell to $80.008 million from $82.056 million in the comparable 2025 period.
- Minor pointNine-month operating loss narrowed to $146.886 million from $198.078 million in the comparable 2025 period.
- Minor pointNine-month net loss narrowed to $165.800 million from $197.196 million; per-share loss improved to $0.62 from $0.74.
- Minor pointFDA regenerative medicine advanced therapy designation was granted September 9, 2026, for obe-cel in lupus and lupus nephritis.
- Minor point. Forward-looking: it has not happened yet and may not happen.CARLYSLE lupus trial updates are scheduled for November 10, 2026, covering adult and adolescent safety and efficacy.
- Minor point. Forward-looking: it has not happened yet and may not happen.CATULUS Phase 2 pediatric leukemia data remain expected by year-end 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.LUMINA Phase 2 lupus nephritis enrollment continues in five countries; Autolus expects data in 2028.
- Minor point. Forward-looking: it has not happened yet and may not happen.ALARIC Phase 1 light-chain amyloidosis data are expected December 12, 2026, at ASH.
Negative
- Moderate pointPerceptive senior secured borrowing primarily drove the quarterly cash increase, adding a debt obligation.
- Moderate pointNine-month selling, general and administrative expenses increased to $117.060 million from $96.082 million in the comparable 2025 period.
- Moderate pointNine-month net other expenses of $18.075 million compared with $4.037 million net other income a year earlier.
- Moderate pointTotal liabilities rose to $495.663 million at September 30, 2026, from $410.939 million at December 31, 2025.
- Moderate pointShareholders’ equity fell to $27.396 million at September 30, 2026, from $178.129 million at December 31, 2025.
3 minor points
- Minor pointQ3 research and development expenses increased to $30.900 million from $27.892 million a year earlier.
- Minor pointQ3 net other expenses increased to $12.045 million from $6.965 million a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Progressive multiple sclerosis data presentation moves to October 2027 to allow longer follow-up to assess clinical benefit.
News Explained
At
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of
$41.2 million , an increase of95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding upper end of$150 million from prior guidance - Gross margin increased to
57% , driven by growing volumes and manufacturing efficiency initiatives - Obe-cel clinical development programs progressing with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)
- Conference call to be held today at 8:30am EST/1:30pm GMT: conference call participants should pre-register using the link at the bottom of this press release
LONDON and GAITHERSBURG, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announces its operational and financial results for the third quarter ended September 30, 2026.
“We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium. Importantly, we also continue to improve the gross margin, with strong execution on manufacturing efficiency initiatives,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
Dr. Itin added, “AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities. We look forward to autoimmune program data presentations at upcoming key medical meetings.”
Product and Pipeline Updates:
- AUCATZYL®
- Autolus reported net product revenue of
$41.2 million for the three months ended September 30, 2026, compared to$21.1 million for the same period the prior year. Net revenues were primarily driven by increasing product demand both within existing treatment centers and expansion into new centers, supplemented by contribution from UK sales.
- Autolus reported net product revenue of
- Obe-cel in pediatric r/r B-ALL
- The Phase 2 portion of the ongoing CATULUS trial of obe-cel in pediatric patients with relapsed or refractory B-cell precursor ALL (r/r B-ALL) is on track and data are expected to be reported at the end of 2027.
- Obe-cel in lupus
- Updated data from the ongoing Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) will be presented in a poster at the American College of Rheumatology (ACR) Annual Meeting, today, November 10, 2026. These data will include safety and efficacy results with up to 25 months follow-up in adult patients and ≥3 months follow-up in adolescent patients.
- LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory lupus nephritis (LN) continues enrolling in five countries and the Company expects to report data in 2028.
- On September 9, 2026, the U.S. Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation to obe-cel for the treatment of SLE and LN. RMAT is designed to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, intended to treat serious or life-threatening diseases.
- Obe-cel in progressive multiple sclerosis
- KOL feedback at the ACTRIMS/ECTRIMS meeting in late October emphasized that initial clinical activity and biomarker data seen across CAR T programs are encouraging but will require longer follow up to judge the clinical benefit in progressive MS patients. Considering this feedback, Autolus plans to move the first data presentation to the ECTRIMS Global meeting in October 2027. At that time, the Company expects to have 12 months or more follow-up for the initial 12 patients dosed, and data in up to 24 patients total. Lymphodepletion with both FLu/Cy as well as bendamustine is being evaluated.
- KOL feedback at the ACTRIMS/ECTRIMS meeting in late October emphasized that initial clinical activity and biomarker data seen across CAR T programs are encouraging but will require longer follow up to judge the clinical benefit in progressive MS patients. Considering this feedback, Autolus plans to move the first data presentation to the ECTRIMS Global meeting in October 2027. At that time, the Company expects to have 12 months or more follow-up for the initial 12 patients dosed, and data in up to 24 patients total. Lymphodepletion with both FLu/Cy as well as bendamustine is being evaluated.
- AUTO8 in Light-Chain Amyloidosis
- The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at ASH in December 2026.
- The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at ASH in December 2026.
Outlook:
Autolus now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding the upper end of
Based on current operating plans, including anticipated AUCATZYL net revenues and proceeds of the combined first and second tranches totaling
Summary of Anticipated News Flow:
| Longer-term follow up data from CARLYSLE trial in patients with severe refractory systemic lupus erythematosus | ACR 2026 November 10, 2026 |
| Initial clinical data from ALARIC Phase 1 trial in patients with light-chain amyloidosis | ASH 2026 December 12, 2026 |
| Initial clinical data from BOBCAT Phase 1 trial in patients with progressive MS | October 2027 |
| Phase 2 data from CATULUS trial in patients with pediatric r/r B-ALL | By year-end 2027 |
| Phase 2 data from LUMINA trial in patients with LN | In 2028 |
Financial Results for the Quarter Ended September 30, 2026
Product revenue, net increased to
Cost of sales decreased to
Research and development expenses increased to
Selling, general and administrative expenses decreased to
Loss from operations for the three months ended September 30, 2026, was
Net loss was
Cash, cash equivalents and marketable securities at September 30, 2026, totaled
| Selected Consolidated Statements of Operations and Comprehensive Loss Data | ||||||||||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||
| Revenue: | ||||||||||||||||||||||||
| Product revenue, net | $ | 41,238 | $ | 21,144 | $ | 113,128 | $ | 51,049 | ||||||||||||||||
| License revenue | — | 50 | 17 | 50 | ||||||||||||||||||||
| Total revenue, net | 41,238 | 21,194 | 113,145 | 51,099 | ||||||||||||||||||||
| Cost and operating expenses: | ||||||||||||||||||||||||
| Cost of sales | (17,927 | ) | (28,643 | ) | (62,963 | ) | (71,039 | ) | ||||||||||||||||
| Research and development expenses, net | (30,900 | ) | (27,892 | ) | (80,008 | ) | (82,056 | ) | ||||||||||||||||
| Selling, general and administrative expenses | (35,946 | ) | (36,280 | ) | (117,060 | ) | (96,082 | ) | ||||||||||||||||
| Loss from operations | (43,535 | ) | (71,621 | ) | (146,886 | ) | (198,078 | ) | ||||||||||||||||
| Other (expense) income: | ||||||||||||||||||||||||
| Total other (expenses) income, net | (12,045 | ) | (6,965 | ) | (18,075 | ) | 4,037 | |||||||||||||||||
| Net loss before income tax | (55,580 | ) | (78,586 | ) | (164,961 | ) | (194,041 | ) | ||||||||||||||||
| Income tax benefit (expense) | 489 | (532 | ) | (839 | ) | (3,155 | ) | |||||||||||||||||
| Net loss | (55,091 | ) | (79,118 | ) | (165,800 | ) | (197,196 | ) | ||||||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||||||||||
| Foreign currency exchange translation adjustment | 484 | (5,868 | ) | (108 | ) | 23,790 | ||||||||||||||||||
| Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of | (6 | ) | 86 | (159 | ) | 464 | ||||||||||||||||||
| Total other comprehensive income (loss), net of tax | 478 | (5,782 | ) | (267 | ) | 24,254 | ||||||||||||||||||
| Total comprehensive loss | ) | ) | ) | ) | ||||||||||||||||||||
| Basic and diluted net loss per ordinary share | $ | (0.21 | ) | $ | (0.30 | ) | $ | (0.62 | ) | $ | (0.74 | ) | ||||||||||||
| Weighted-average basic and diluted ordinary shares | 266,203,656 | 266,141,431 | 266,168,856 | 266,136,518 | ||||||||||||||||||||
| Financial Results for the Period Ended September 30, 2026 Selected Consolidated Balance Sheet Data (In thousands) | ||||||
| September 30, | December 31, | |||||
| 2026 | 2025 | |||||
| Assets | ||||||
| Cash and cash equivalents | $ | 245,405 | $ | 104,132 | ||
| Marketable securities - Available-for-sale debt securities | $ | 2,972 | $ | 196,578 | ||
| Total current assets | $ | 366,784 | $ | 435,915 | ||
| Total assets | $ | 523,059 | $ | 589,068 | ||
| Liabilities and shareholders’ equity | ||||||
| Total current liabilities | $ | 98,647 | $ | 73,440 | ||
| Total liabilities | $ | 495,663 | $ | 410,939 | ||
| Total shareholders’ equity | $ | 27,396 | $ | 178,129 | ||
Conference Call
Management will host a conference call and webcast today at 8:30am EDT/1:30pm GMT to discuss the company’s financial results. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website at https://www.autolus.com/investor-relations-media/events/.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
About AUCATZYL® (obecabtagene autoleucel; obe-cel)
AUCATZYL is a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. AUCATZYL is designed with a fast target binding off-rate to minimize excessive activation of the programmed T cells. AUCATZYL was approved by the FDA for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia on November 8, 2024, and was granted conditional marketing authorization by MHRA in the UK and EMA in the EU in 2025.
INDICATION
AUCATZYL® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
IMPORTANT SAFETY INFORMATION
| WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES | ||
| ||
| ||
|
WARNINGS AND PRECAUTIONS
Cytokine Release Syndrome (CRS)
Cytokine Release Syndrome (CRS) occurred following treatment with AUCATZYL. CRS was reported in
Cytokine Release Syndrome (CRS) occurred following treatment with AUCATZYL. CRS was reported in
Prior to administering AUCATZYL, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage CRS. During and following treatment with AUCATZYL, closely monitor patients for signs and symptoms of CRS daily for at least 7 days following each infusion. Continue to monitor patients for CRS for at least 2 weeks following each infusion with AUCATZYL. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, immediately evaluate the patient for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.
Neurologic Toxicities
Neurologic toxicities including Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), which were fatal or life-threatening, occurred following treatment with AUCATZYL. Neurologic toxicities were reported in
The median time to onset of neurologic toxicities was 10 days (range: 1 to 246 days) with a median duration of 13 days (range: 1 to 904 days). Fifty-five percent of patients (35/64) experienced neurologic toxicities after the first infusion but prior to the second infusion of AUCATZYL with a median time to onset of 6 days (range: 1 to 11 days). Among patients with neurologic toxicities, the most common symptoms (>
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
ICANS events occurred in
During and following AUCATZYL administration, closely monitor patients for signs and symptoms of Neurologic Toxicity/ICANS. Following treatment with AUCATZYL, monitor patients daily for at least 7 days. Continue to monitor patients for at least 2 weeks following treatment with AUCATZYL. Avoid driving for at least 2 weeks after each infusion. Counsel patients to seek medical attention should signs or symptoms of neurologic toxicity/ ICANS occur. At the first sign of Neurologic Toxicity/ICANS, immediately evaluate patients for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.
Prolonged Cytopenias
Patients may exhibit cytopenias including anemia, neutropenia, and thrombocytopenia for several weeks after treatment with lymphodepleting chemotherapy and AUCATZYL. In patients who were responders to AUCATZYL, Grade ≥ 3 cytopenias that persisted beyond Day 30 following AUCATZYL infusion were observed in
Infections
Severe, including life-threatening and fatal infections occurred in patients after AUCATZYL infusion. Non-COVID-19 infections of all grades occurred in
Grade 3 or higher febrile neutropenia was observed in
Viral reactivation, potentially severe or life-threatening, can occur in patients treated with drugs directed against B cells. There is no experience with manufacturing AUCATZYL for patients with a positive test for human immunodeficiency virus (HIV) or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV). Perform screening for HBV, HCV and HIV in accordance with clinical guidelines before collection of cells for manufacturing.
Hypogammaglobulinemia
Hypogammaglobulinemia and B-cell aplasia can occur in patients after AUCATZYL infusion. Hypogammaglobulinemia was reported in
Immunoglobulin levels should be monitored after treatment with AUCATZYL and managed per institutional guidelines including infection precautions, antibiotic or antiviral prophylaxis, and immunoglobulin replacement.
The safety of immunization with live viral vaccines during or following treatment with AUCATZYL has not been studied. Vaccination with live viral vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy treatment, during AUCATZYL treatment, and until immune recovery following treatment with AUCATZYL.
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
HLH/MAS including fatal and life-threatening reactions occurred after treatment with AUCATZYL. HLH/MAS was reported in
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO), an excipient used in AUCATZYL. Observe patients for hypersensitivity reactions during and after AUCATZYL infusion.
Secondary Malignancies
Patients treated with AUCATZYL may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Autolus at 1-855-288-5227 for reporting and to obtain instructions on the collection of patient samples for testing.
Adverse Reactions
The safety of AUCATZYL was evaluated in the FELIX study in which 100 patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) received AUCATZYL at a median dose of 410 × 106 CD19 CAR-positive viable T cells (range: 10 to 480 × 106 CD19 CAR-positive viable T cells with
The most common serious adverse reactions of any Grade (incidence ≥
Please see full Prescribing Information, including BOXED WARNING and Medication Guide.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may," “will,” “could," “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding Autolus’ future expectations, plans and prospects, including guidance on 2026 AUCATZYL net product revenue and gross margin, and the impact of recently announced restructuring activities; Autolus’ anticipated cash runway; the therapeutic potential and expected clinical benefits of AUCATZYL for adult patients with r/r B-ALL and obe-cel in additional indications including LN and progressive MS; Autolus’ ability to generate revenues from AUCATZYL; Autolus’ ability to obtain and maintain regulatory approval for obe-cel for adult r/r B-ALL in additional territories and the timing thereof; expectations regarding the commercialization, marketing and manufacturing of AUCATZYL for adult r/r B-ALL, including expanding into additional territories and the related timing of reaching patients in such territories; the development of obe-cel in autoimmune indications and of additional product candidates, including statements regarding the initiation, timing, progress and the results of clinical studies or trials and related preparatory work; the period during which the results of clinical studies or trials will become available; Autolus’ plans to expand, develop and enhance its manufacturing activities; and Autolus’ pursuit of expanded market access across Europe. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks identified in the section titled “Risk Factors” in Autolus’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC), on March 27, 2026 and any of its subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the SEC. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing Autolus’ views as of any date subsequent to the date of this press release.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
1 Gross margin percentage represents gross margin (net product revenue less cost of sales) divided by net product revenue
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Autolus AUTL’s third-quarter 2026 AUCATZYL sales and updated revenue outlook?
AUCATZYL net product revenue was $41.2 million in Q3 2026, up 95% year over year. Autolus now expects full-year 2026 AUCATZYL net product revenue at or above the $150 million upper end of its prior guidance.
Why did Autolus move its first progressive multiple sclerosis data presentation to October 2027?
Autolus moved the presentation to October 2027 after specialist feedback emphasized longer follow-up to judge clinical benefit. At the ECTRIMS Global meeting, the company expects at least 12 months of follow-up for the initial 12 patients dosed and data in up to 24 patients total.
What follow-up will Autolus present from the CARLYSLE lupus trial?
The CARLYSLE update will include safety and efficacy results with up to 25 months of follow-up in adults and ≥3 months in adolescents. The ongoing Phase 1 trial studies obe-cel in severe refractory systemic lupus erythematosus, with the poster scheduled for the American College of Rheumatology Annual Meeting on November 10, 2026.